Paper Details

  1. Home
  2. Paper Details

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.

Author: BauesChristian, BorchmannPeter, DiehlVolker, DietleinMarkus, DührsenUlrich, EichHans, EngertAndreas, FuchsMichael, GoergenHelen, GreilRichard, HertensteinBernd, KellerUlrich Bernd, KobeCarsten, KrauseStefan W, KuhnertGeorg, LohriAndreas, MaschmeyerGeorg, MeissnerJulia, RosenwaldAndreas, SasseStephanie, SchäferErhardt, SoeklerMartin, ThiemerJulia, ToppMax S, ViardotAndreas, VogelhuberMartin, WilhelmMartin, ZijlstraJosée M, von TresckowBastian

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the role of positron emission tomography (PET) after 2 cycles of ABVD chemotherapy (PET-2) in guiding treatment for patients with early-stage favorable Hodgkin lymphoma (HL).
Paper Details　
Original Abstract of the Article :
Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients with early-stage favorable Hodgkin lymphoma (HL). However, the role of radiotherapy has been challenged. Positron emission tomography (P...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.19.00964

データ提供：米国国立医学図書館（NLM）

PET-Guided Treatment for Early-Stage Hodgkin Lymphoma

The field of

oncology

is constantly evolving, seeking more precise and effective treatments for

cancer

. This study explores the potential of

positron emission tomography

(PET) to guide treatment for early-stage

Hodgkin lymphoma

(HL), a type of cancer affecting the lymph nodes.

Precision Treatment for Hodgkin Lymphoma

The study highlights the role of PET scans in predicting individual outcomes and tailoring treatment plans. The researchers found that PET scans after two cycles of

ABVD

chemotherapy (PET-2) can help determine which patients are likely to benefit from radiotherapy. This approach is like a camel caravan using a compass to navigate the desert – by relying on accurate data, doctors can make more informed decisions about treatment, leading to better outcomes for patients.

The Promise of Personalized Cancer Care

Advancements in imaging techniques like PET are transforming the way we treat cancer. By enabling more precise diagnosis and treatment planning, these technologies offer hope for improved outcomes and a better quality of life for patients. Just as a camel caravan relies on a skilled guide to navigate the treacherous desert, cancer patients benefit from the expertise of skilled oncologists who utilize advanced technologies to personalize their care.

Dr.Camel's Conclusion

This research showcases the power of personalized medicine in the fight against cancer. By using PET-guided treatment strategies, oncologists can make more informed decisions, leading to improved outcomes for patients with HL. This is a testament to the continuous progress being made in the field of oncology, offering hope for a future where cancer is more effectively treated and managed.

Date :
  1. Date Completed 2020-06-15
  2. Date Revised 2020-12-10
Further Info :

Pubmed ID

31498753

DOI: Digital Object Identifier

10.1200/JCO.19.00964

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.